Trials / Sponsors / ADARx Pharmaceuticals, Inc.
ADARx Pharmaceuticals, Inc.
Industry · 9 registered clinical trials — 6 currently recruiting.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Recruiting | Chinese Adults With Kidney Disease Immunoglobulin A Nephropathy (IgAN), Complement 3 Glomerulopathy (C3G), IC-MPGN | Phase 2 | 2026-07-23 |
| Not Yet Recruiting | Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE) Hereditary Angioedema (HAE), Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2 | Phase 3 | 2026-04-01 |
| Recruiting | Phase 2 Study of ADX-038 in Participants With Geographic Atrophy Geographic Atrophy Secondary to Age-related Macular Degeneration | Phase 2 | 2025-11-10 |
| Recruiting | Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease IgAN, C3G, Complement-mediated Kidney Disease | Phase 2 | 2025-08-28 |
| Recruiting | STOP-HAE: A Phase 3 Study of ADX-324 in HAE Hereditary Angioedema, HAE, Hereditary Angioedema - Type 1 | Phase 3 | 2025-08-28 |
| Recruiting | Phase 1 Study of ADX-626 in Healthy Participants Healthy Adult Participants | Phase 1 | 2025-08-12 |
| Active Not Recruiting | Safety, Tolerability, PK and PD of ADX-850 in Participants With Hypertension Hypertension, Hypertension,Essential | Phase 1 | 2024-03-21 |
| Active Not Recruiting | Safety, Tolerability, PK and PD of ADX-038 in Healthy Participants and Paroxysmal Nocturnal Hemoglobinuria (PN Paroxysmal Nocturnal Hemoglobinuria (PNH) | Phase 1 / Phase 2 | 2023-08-07 |
| Active Not Recruiting | Safety, Tolerability, PK, PD of ADX-324 in Healthy Volunteers and Hereditary Angioedema Patients Hereditary Angioedema | Phase 1 / Phase 2 | 2022-12-14 |